ArticleJournal of thrombosis and thrombolysis2026
Venous thromboembolism mortality trends among us adults with cancer, 1999-2024.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thrombosis: focus on molecular mechanisms, biomarkers and cardio-oncology.Journal of thrombosis and thrombolysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Venous thromboembolism (VTE) remains a leading preventable cause of death among cancer patients in the United States. Despite advances in thromboprophylaxis and clinical guideline development, nationally representative longitudinal data on VTE-related mortality trends in this population remain limited. Using CDC WONDER multiple-cause-of-death records (1999-2024), we identified VTE-related deaths (ICD-10: I26, I80-I82) among US adults aged ≥ 25 years with a concurrent cancer diagnosis (C00-C97). Age-adjusted mortality rates (AAMRs) per 100,000 persons and average annual percent changes (AAPCs) with 95% confidence intervals were estimated using Joinpoint regression and stratified by sex, race/ethnicity, age group, urbanization level, Census region, and state. Among 312,260 VTE-related cancer deaths, the national AAMR rose from 3.92 to 7.58 per 100,000 (AAPC: 2.40%; p < 0.001), with the sharpest acceleration during 2019-2022 (APC: 12.78%; p = 0.031). Increases were statistically significant across all demographic and geographic subgroups, though the magnitude varied considerably. By sex, mortality rose more steeply among women (AAPC: 2.61%; p < 0.001) than men (AAPC: 2.14%; p < 0.001). By race/ethnicity, the fastest increases occurred among non-Hispanic American Indian/Alaska Native (3.73%; p < 0.001), non-Hispanic Asian/Pacific Islander (3.62%; p < 0.001), Hispanic (3.12%; p < 0.001), and non-Hispanic Black (3.07%; p < 0.001) populations, compared with non-Hispanic White individuals, who showed the slowest rise (2.45%; p < 0.001). By age group, AAPCs ranged from 2.09% among adults 55-64 years (p < 0.001) to 4.19% among those ≥ 85 years (p < 0.001), indicating a disproportionate burden among the oldest patients. By Census region, the West (3.02%; p < 0.001) and South (2.70%; p < 0.001) exhibited faster growth than the Midwest (2.33%; p < 0.001) and Northeast (2.13%; p < 0.001). At the state level, AAPCs ranged from - 2.76% in Maine (p = 0.034), the only state with a significant decline, to 6.15% in Colorado (p < 0.001), with 39 of 51 jurisdictions showing statistically significant increases. VTE-related mortality among US adults nearly doubled from 1999 to 2024. A marked surge was observed during the COVID-19 pandemic, followed by stabilization after 2022. Persistent disparities across demographic and geographic subgroups underscore the urgent need for equity-oriented prevention strategies.
Identifiers
42693319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.